Xoma Corp. (XOMA) Receives $7.33 Consensus PT from Analysts
Shares of Xoma Corp. (NASDAQ:XOMA) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock. Six investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $7.33.
A number of research analysts recently commented on XOMA shares. Zacks Investment Research raised shares of Xoma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Wednesday, October 26th. Jefferies Group reiterated a “hold” rating on shares of Xoma Corp. in a research note on Friday, August 5th. Cowen and Company reiterated a “market perform” rating on shares of Xoma Corp. in a research note on Monday, September 19th. Ladenburg Thalmann reiterated a “neutral” rating on shares of Xoma Corp. in a research note on Wednesday. Finally, Wedbush cut shares of Xoma Corp. from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $17.00 to $14.00 in a research note on Monday.
Xoma Corp. (NASDAQ:XOMA) opened at 6.97 on Tuesday. The firm has a market capitalization of $42.02 million, a price-to-earnings ratio of 30.84 and a beta of 3.71. Xoma Corp. has a one year low of $4.70 and a one year high of $32.40. The firm’s 50-day moving average is $3.86 and its 200 day moving average is $1.44.
Xoma Corp. (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($2.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.40) by $0.32. The company had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $1.29 million. The firm’s revenue was down 69.1% compared to the same quarter last year. Analysts forecast that Xoma Corp. will post ($9.07) EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Spark Investment Management LLC boosted its position in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the last quarter. Bellevue Group AG bought a new position in Xoma Corp. during the first quarter valued at approximately $174,000. Paloma Partners Management Co bought a new position in Xoma Corp. during the second quarter valued at approximately $185,000. Wedbush Securities Inc. boosted its position in Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock valued at $223,000 after buying an additional 15,827 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Xoma Corp. during the first quarter valued at approximately $374,000.
Xoma Corp. Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Stock Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related stocks with our FREE daily email newsletter.